Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study

Journal of Viral Hepatitis

Volumn 23, Issue 12, 2016, Pages 977-984

  Nishikawa, H ^a   Enomoto, H ^a   Iwata, Y ^a   Kishino, K ^a   Shimono, Y ^a   Hasegawa, K ^a   Nakano, C ^a   Takata, R ^a   Nishimura, T ^a   Yoh, K ^a   Ishii, A ^a   Aizawa, N ^a   Sakai, Y ^a   Ikeda, N ^a   Takashima, T ^a   Iijima, H ^a   Nishiguchi, S ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

chronic hepatitis; comparative study; liver fibrosis marker; Wisteria floribunda agglutinin positive Mac 2 binding protein

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CELL PROTEIN; CHOLESTEROL; GLUCOSE; HYALURONIC ACID; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ POSITIVE MAC 2 BINDING PROTEIN; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; PROTEIN BINDING; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; THROMBOCYTE COUNT; ADOLESCENT; BLOOD; CHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; SERUM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLANT LECTINS; PROTEIN BINDING; RECEPTORS, N-ACETYLGLUCOSAMINE; SERUM; YOUNG ADULT;

EID: 84979742721     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12575     Document Type: Article

References (37)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
2. Brahmania M, Feld J, Arif A, Janssen HL. New therapeutic agents for chronic hepatitis B. Lancet Infect Dis. 2016;16:e10–e21.
3. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–1135.
4. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429–2438.
5. Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284–306.
6. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastoenterol Hepatol. 1997;12:S294–S298.
7. Kim BK, Kim do Y, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int 2010;30:546–553.
8. Shimamatsu K, Kage M, Nakashima O, Kojiro M. Pathomorphological study of HCV antibody-positive liver cirrhosis. J Gastroenterol Hepatol. 1994;9:624–630.
9. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology. 1997;25:1028–1031.
10. Fujiyoshi M, Kuno A, Gotoh M, et al. Hepatitis Glyco-biomarker Study Group. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015;50:1134–1144.
11. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015;50:76–84.
12. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563–1570.
13. Nishikawa H, Enomoto H, Iwata Y, et al. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level and high sensitivity C reactive protein concentration in autoimmune hepatitis. Hepatol Res. 2016;46:613–621.
14. Nishikawa H, Enomoto H, Iwata Y, et al. Impact of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis. Hepatol Res. 2016;46:575–583.
15. Nishikawa H, Enomoto H, Iwata Y, et al. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level in non-alcoholic steatohepatitis. Hepatol Res. 2016. Feb 2. doi: 10.1111/hepr.12662. [Epub ahead of print].
16. Tamaki N, Kurosaki M, Kuno A, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res. 2015;45:E82–E88.
17. Hanai T, Shiraki M, Ohnishi S, et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015;45:1083–1090.
18. Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015;110:857–864.
19. Nishikawa H, Enomoto H, Iwata Y, et al. Clinical implication of serum WFA+ -M2BP level on Hepatitis B e Antigen loss or Seroconversion in Hepatitis B e Antigen-positive patients. Hepatol Res. 2016. Jan 19. doi: 10.1111/hepr.12655. [Epub ahead of print].
20. Ura K, Furusyo N, Ogawa E, et al. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2016;43:114–124.
21. Toyoda H, Kumada T, Tada T, et al. Serum WFA(+) -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2016;36:293–301.
22. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726–736.
23. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
24. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292–302.
25. Ray Kim W, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–780.
26. Sterling RK, Lissen E, Clumeck N, et al. APRICOT clinical investigators: development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
27. Ishii A, Nishikawa H, Enomoto H, et al. Clinical implication of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment naïve chronic hepatitis B. Hepatol Res. 2016. Mar 18. doi: 10.1111/hepr.12703. [Epub ahead of print].
28. Nishikawa H, Enomoto H, Nasu A, et al. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res. 2014;44:E397–E407.
29. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15–20.
30. Rostami S, Parsian H. Hyaluronic acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis. Hepat Mon. 2013;13:e13787.
31. Wong CS, Gibson PR. Effects of eating on plasma hyaluronan in patients with cirrhosis: its mechanism and influence on clinical interpretation. J Gastroenterol Hepatol. 1998;13:1218–1224.
32. Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 2015;204:5–10.
33. Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 2015;35(Suppl 1):78–81.
34. Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol. 2014;20:228–236.
35. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–S68.
36. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology. 1993;104:595–603.
37. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847.